1
|
Nakyanzi A, Naddunga F, Bulterys MA, Mujugira A, Wyatt MA, Kamusiime B, Nalumansi A, Kasiita V, Peacock S, Celum CL, Ware NC. " It Soothes Your Heart": A Multimethod Study Exploring Acceptability of Point-of-Care Viral Load Testing among Ugandan Pregnant and Postpartum Women Living with HIV. Diagnostics (Basel) 2023; 14:72. [PMID: 38201381 PMCID: PMC10795616 DOI: 10.3390/diagnostics14010072] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/16/2023] [Revised: 11/16/2023] [Accepted: 11/24/2023] [Indexed: 01/12/2024] Open
Abstract
BACKGROUND High adherence to antiretroviral therapy (ART) is critical for achieving viral suppression and preventing onward HIV transmission. ART continuation can be challenging for pregnant women living with HIV (PWLHIV), which has critical implications for risk of vertical HIV transmission. Point-of-care viral load (POC VL) testing has been associated with improved treatment and retention outcomes. We sought to explore acceptability of POC VL testing among Ugandan PWLHIV during pregnancy and postpartum. METHODS This multimethod analysis drew on quantitative and qualitative data collected between February and December 2021. Quantitatively, we used an intent-to-treat analysis to assess whether randomization to clinic-based POC VL testing during pregnancy and infant testing at delivery was associated with improved viral suppression (≤50 copies/mL) by 3 months postpartum compared to standard-of-care (SOC) VL testing through a central laboratory, adjusting for factorial randomization for the male partner testing strategy. Additionally, a subset of 22 PWLHIV in the POC VL arm participated in in-depth qualitative interviews. We inductively analyzed transcripts to develop categories representing concepts that characterized women's perceptions of POC VL testing during pregnancy and at delivery and ways that POC VL testing may have impacted their ART adherence and viral suppression. Key themes around women's perceptions of POC VL testing were then organized into main categories. RESULTS Overall, 151 PWLHIV were enrolled into the study, 77 (51%) of whom were randomized to receive POC VL testing during pregnancy and at delivery. Women reported in qualitative interviews that POC VL testing had (1) motivated their ART adherence during pregnancy and postpartum and that they felt this testing method had (2) helped them protect their infants from acquiring HIV and (3) improved their emotional wellbeing. CONCLUSIONS POC VL testing was highly acceptable among Ugandan PWLHIV and was viewed as an important tool that women believed improved their ART adherence, gave them information necessary to protect their infants from vertical HIV acquisition, and improved their emotional wellbeing. These findings support the global scale-up of POC VL testing in settings with high HIV burden, especially for PWLHIV who may be at risk of treatment disruptions or loss to follow-up.
Collapse
Affiliation(s)
- Agnes Nakyanzi
- Infectious Diseases Institute, Makerere University, Kampala P.O. Box 7072, Uganda; (F.N.); (A.M.); (B.K.); (A.N.); (V.K.)
| | - Faith Naddunga
- Infectious Diseases Institute, Makerere University, Kampala P.O. Box 7072, Uganda; (F.N.); (A.M.); (B.K.); (A.N.); (V.K.)
| | - Michelle A. Bulterys
- Department of Global Health, University of Washington, Seattle, WA 98109, USA; (M.A.B.); (S.P.); (C.L.C.)
| | - Andrew Mujugira
- Infectious Diseases Institute, Makerere University, Kampala P.O. Box 7072, Uganda; (F.N.); (A.M.); (B.K.); (A.N.); (V.K.)
- Department of Global Health, University of Washington, Seattle, WA 98109, USA; (M.A.B.); (S.P.); (C.L.C.)
| | - Monique A. Wyatt
- Department of Global Health and Social Medicine, Harvard Medical School, Boston, MA 02115, USA; (M.A.W.); (N.C.W.)
- Harvard Global, Cambridge, MA 02138, USA
| | - Brenda Kamusiime
- Infectious Diseases Institute, Makerere University, Kampala P.O. Box 7072, Uganda; (F.N.); (A.M.); (B.K.); (A.N.); (V.K.)
| | - Alisaati Nalumansi
- Infectious Diseases Institute, Makerere University, Kampala P.O. Box 7072, Uganda; (F.N.); (A.M.); (B.K.); (A.N.); (V.K.)
| | - Vicent Kasiita
- Infectious Diseases Institute, Makerere University, Kampala P.O. Box 7072, Uganda; (F.N.); (A.M.); (B.K.); (A.N.); (V.K.)
| | - Sue Peacock
- Department of Global Health, University of Washington, Seattle, WA 98109, USA; (M.A.B.); (S.P.); (C.L.C.)
| | - Connie L. Celum
- Department of Global Health, University of Washington, Seattle, WA 98109, USA; (M.A.B.); (S.P.); (C.L.C.)
- Departments of Medicine and Epidemiology, University of Washington, Seattle, WA 98109, USA
| | - Norma C. Ware
- Department of Global Health and Social Medicine, Harvard Medical School, Boston, MA 02115, USA; (M.A.W.); (N.C.W.)
- Department of Medicine, Brigham and Women’s Hospital, Boston, MA 02115, USA
| |
Collapse
|
2
|
Birhanu S, Winterhalter FS, Stupp P, Cates M, Rottinghaus E, Yavo D, Wray-Gordon F, Lupoli K, Ndongmo CB, Longwe H, Reid GA, Metz M, Saito S, McCracken S, Brown K, Voetsch AC, Duong YT, Parekh BS, Patel HK. Point of Care CD4 Testing in National Household Surveys - Results and Quality Indicators from Eleven Population-Based HIV Impact Assessment (PHIA) Surveys. Microbiol Spectr 2023; 11:e0314822. [PMID: 37071009 PMCID: PMC10269725 DOI: 10.1128/spectrum.03148-22] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/11/2022] [Accepted: 03/13/2023] [Indexed: 04/19/2023] Open
Abstract
Population-based HIV Impact Assessments (PHIAs) are national household (HH) surveys that provide HIV diagnosis and CD4 testing with an immediate return of results. Accurate CD4 results improve HIV-positive participants' clinical care and inform the effectiveness of HIV programs. Here, we present CD4 results from the PHIA surveys that were conducted in 11 countries in sub-Saharan Africa between 2015 and 2018. All of the HIV-positive participants and 2 to 5% of the HIV-negative participants were offered Pima CD4 (Abbott, IL, USA) point-of-care (POC) tests. The quality of the CD4 test was ensured by conducting instrument verification, comprehensive training, quality control, a review of testing errors and an analysis of unweighted CD4 data by HIV status, age, gender, and antiretroviral (ARV) treatment status. Overall, CD4 testing was completed for 23,085 (99.5%) of the 23,209 HIV-positive and 7,329 (2.7%) of the 270,741 negative participants in 11 surveys. The instrument error rate was 11.3% (range, 4.4% to 15.7%). The median CD4 values among HIV-positive and HIV-negative participants (aged 15+) were 468 cells/mm3 (interquartile range [IQR], 307 to 654) and 811 cells/mm3 (IQR, 647 to 1,013), respectively. Among the HIV-positive participants (aged 15+), those with detectable ARVs had higher CD4 values (508 cells/mm3) than those with undetectable ARVs (385.5 cells/mm3). Among the HIV-positive participants (aged 15+), 11.4% (2,528/22,253) had a CD4 value of less than 200 cells/mm3, and approximately half of them (1,225/2,528 = 48.5%) had detectable ARVs, whereas 51.5% (1,303/2,528) had no detectable ARVs (P < 0.0001). We successfully implemented high quality POC CD4 testing using Pima instruments. Our data come from nationally representative surveys in 11 countries and provide unique insights regarding the CD4 distribution among HIV-positive individuals as well as the baseline CD4 values among HIV-negative individuals. IMPORTANCE The manuscript describes CD4 levels among HIV-positive individuals and baseline CD4 levels among HIV-negative individuals from 11 sub-Saharan countries, thereby highlighting the importance of CD4 markers in the context of the HIV epidemic. Despite increased ARV access in each country, advanced HIV disease (CD4 < 200 cells/mm3) persists among approximately 11% of HIV-positive individuals. Therefore, it is important that our findings are shared with the scientific community to assist with similar implementations of point-of-care testing and to conduct a review of HIV programmatic gaps.
Collapse
Affiliation(s)
- Sehin Birhanu
- Division of Global HIV and TB, Center for Global Health, CDC, Atlanta, Georgia, USA
| | | | - Paul Stupp
- Division of Global HIV and TB, Center for Global Health, CDC, Atlanta, Georgia, USA
| | - Melissa Cates
- Division of Global HIV and TB, Center for Global Health, CDC, Atlanta, Georgia, USA
| | - Erin Rottinghaus
- Division of Global HIV and TB, Center for Global Health, CDC, Atlanta, Georgia, USA
| | - Daniel Yavo
- Division of Global HIV and TB, Center for Global Health, CDC, Atlanta, Georgia, USA
| | - Floris Wray-Gordon
- Division of Global HIV and TB, Center for Global Health, CDC, Atlanta, Georgia, USA
| | - Kathryn Lupoli
- Division of Global HIV and TB, Center for Global Health, CDC, Atlanta, Georgia, USA
| | - Clement B. Ndongmo
- Division of Global HIV and TB, Center for Global Health, CDC, Atlanta, Georgia, USA
| | | | - Giles A. Reid
- ICAP at Columbia University, New York, New York, USA
| | - Melissa Metz
- ICAP at Columbia University, New York, New York, USA
| | - Suzue Saito
- ICAP at Columbia University, New York, New York, USA
| | - Stephen McCracken
- Division of Global HIV and TB, Center for Global Health, CDC, Atlanta, Georgia, USA
| | - Kristin Brown
- Division of Global HIV and TB, Center for Global Health, CDC, Atlanta, Georgia, USA
| | - Andrew C. Voetsch
- Division of Global HIV and TB, Center for Global Health, CDC, Atlanta, Georgia, USA
| | - Yen T. Duong
- ICAP at Columbia University, New York, New York, USA
| | - Bharat S. Parekh
- Division of Global HIV and TB, Center for Global Health, CDC, Atlanta, Georgia, USA
| | - Hetal K. Patel
- Division of Global HIV and TB, Center for Global Health, CDC, Atlanta, Georgia, USA
| |
Collapse
|
3
|
Aniekwe C, Cuffe K, Audu I, Nalda N, Ibezim B, Nnakwe M, Anazodo T, Dada M, Rottinghaus Romano E, Okoye M, Martin M, Shrivastava R. Assessing the effect of electronic health information exchange on the completeness and validity of data for measuring viral load testing turnaround time in Nigeria. Int J Med Inform 2023; 174:105059. [PMID: 37002987 DOI: 10.1016/j.ijmedinf.2023.105059] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/28/2022] [Revised: 02/13/2023] [Accepted: 03/24/2023] [Indexed: 03/29/2023]
Abstract
INTRODUCTION Implementation of health information exchange has been shown to result in several benefits which includes the improvement in the completeness and timeliness of data for public health program monitoring and surveillance. OBJECTIVE The objective of this study was to assess the effect of implementing an electronic health information exchange (HIE) on the quality of data available to measure HIV viral load testing turnaround time (TAT) in Nigeria. METHODS We measured viral load data validity and completeness before the implementation of electronic health information exchange, and 6 months after implementation. Records of specimens collected at 30 healthcare facilities and tested in 3 Polymerase Chain Reaction (PCR) labs were analyzed. We define data completeness as the percentage of non-missing values and measured this value by specimens and by data elements in the dataset for calculating TAT. To examine data validity, we classified TAT segments with negative values and date fields that were not in International Organization for Standardization(ISO) standard date format as invalid. Validity was measured by specimens and by each TAT segment. Pearson's chi square was used to assess for improvements in validity and completeness post implementation of HIE. RESULTS 15,226 records of specimens were analyzed at baseline and 18,022 records of specimens analyzed at endline. Data completeness for all specimens recorded increased significantly from 47% before HIE implementation to 67% six months after implementation (p < 0.01). Data validity also increased from 90% before implementation to 91% after implementation (p < 0.01) CONCLUSION: Our study demonstrated evidence of significant improvement in the quality of data available to measure viral load turnaround time with the implementation of HIE.
Collapse
|
4
|
Fonjungo PN, Lecher S, Zeh C, Rottinghaus E, Chun H, Adje-Toure C, Lloyd S, Mwangi JW, Mwasekaga M, Eshete YM, Pati R, Mots’oane T, Mitruka K, Beukes A, Mwangi C, Bowen N, Hamunime N, Beard RS, Kabuje A, Nabadda S, Auld AF, Balachandra S, Zungu I, Kandulu J, Alemnji G, Ehui E, Alexander H, Ellenberger D. Progress in scale up of HIV viral load testing in select sub-Saharan African countries 2016-2018. PLoS One 2023; 18:e0282652. [PMID: 36920918 PMCID: PMC10016655 DOI: 10.1371/journal.pone.0282652] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/30/2022] [Accepted: 02/19/2023] [Indexed: 03/16/2023] Open
Abstract
INTRODUCTION We assessed progress in HIV viral load (VL) scale up across seven sub-Saharan African (SSA) countries and discussed challenges and strategies for improving VL coverage among patients on anti-retroviral therapy (ART). METHODS A retrospective review of VL testing was conducted in Côte d'Ivoire, Kenya, Lesotho, Malawi, Namibia, Tanzania, and Uganda from January 2016 through June 2018. Data were collected and included the cumulative number of ART patients, number of patients with ≥ 1 VL test result (within the preceding 12 months), the percent of VL test results indicating viral suppression, and the mean turnaround time for VL testing. RESULTS Between 2016 and 2018, the proportion of PLHIV on ART in all 7 countries increased (range 5.7%-50.2%). During the same time period, the cumulative number of patients with one or more VL test increased from 22,996 to 917,980. Overall, viral suppression rates exceeded 85% for all countries except for Côte d'Ivoire at 78% by June 2018. Reported turnaround times for VL testing results improved in 5 out of 7 countries by between 5.4 days and 27.5 days. CONCLUSIONS These data demonstrate that remarkable progress has been made in the scale-up of HIV VL testing in the seven SSA countries.
Collapse
Affiliation(s)
- Peter N. Fonjungo
- Division of Global HIV and TB, Center for Global Health, CDC, Atlanta, Georgia, United States of America
- * E-mail:
| | - Shirley Lecher
- Division of Global HIV and TB, Center for Global Health, CDC, Atlanta, Georgia, United States of America
| | - Clement Zeh
- Division of Global HIV and TB, Center for Global Health, CDC, Atlanta, Georgia, United States of America
| | - Erin Rottinghaus
- Division of Global HIV and TB, Center for Global Health, CDC, Atlanta, Georgia, United States of America
| | - Helen Chun
- Division of Global HIV and TB, Center for Global Health, CDC, Atlanta, Georgia, United States of America
| | - Christiane Adje-Toure
- Division of Global HIV and TB, Center for Global Health, CDC, Abidjan, Côte d’Ivoire
| | - Spencer Lloyd
- Division of Global HIV and TB, Center for Global Health, CDC, Atlanta, Georgia, United States of America
| | - Jane W. Mwangi
- Division of Global HIV and TB, Center for Global Health, CDC, Nairobi, Kenya
| | - Michael Mwasekaga
- Division of Global HIV and TB, Center for Global Health, CDC, Dar es Salaam, Tanzania
| | | | - Rituparna Pati
- Division of Global HIV and TB, Center for Global Health, CDC, Atlanta, Georgia, United States of America
| | | | - Kiren Mitruka
- Division of Global HIV and TB, Center for Global Health, CDC, Atlanta, Georgia, United States of America
| | - Anita Beukes
- Namibia Institute of Pathology, Windhoek, Namibia
| | - Christina Mwangi
- Division of Global HIV and TB, Center for Global Health, CDC, Kampala, Uganda
| | | | | | - Rachel S. Beard
- Division of Global HIV and TB, Center for Global Health, CDC, Windhoek, Namibia
| | | | | | - Andrew F. Auld
- Division of Global HIV and TB, Center for Global Health, CDC, Lilongwe, Malawi
| | - Shirish Balachandra
- Division of Global HIV and TB, Center for Global Health, CDC, Abidjan, Côte d’Ivoire
| | - Innocent Zungu
- Division of Global HIV and TB, Center for Global Health, CDC, Lilongwe, Malawi
| | | | - George Alemnji
- Office of the Global AIDS Coordinator and Health Diplomacy, U.S. Department of State, Washington, DC, United States of America
| | - Eboi Ehui
- Ministry of Health, Abidjan, Côte D’Ivoire
| | - Heather Alexander
- Division of Global HIV and TB, Center for Global Health, CDC, Atlanta, Georgia, United States of America
| | - Dennis Ellenberger
- Division of Global HIV and TB, Center for Global Health, CDC, Atlanta, Georgia, United States of America
| |
Collapse
|
5
|
Hussien A, Boka A, Fantu A. Vulnerability to human immunodeficiency virus infection and associated factors among married women in northwest Ethiopia: a cross-sectional study. KOREAN JOURNAL OF WOMEN HEALTH NURSING 2022; 28:307-316. [PMID: 36617482 PMCID: PMC9830114 DOI: 10.4069/kjwhn.2022.12.02] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/19/2022] [Accepted: 12/02/2022] [Indexed: 12/31/2022] Open
Abstract
PURPOSE This study investigated the vulnerability to human immunodeficiency virus (HIV) infection and associated factors among married women in northwest Ethiopia. METHODS A community-based cross-sectional survey (n=657) was conducted from April 1 to 15,2020, in Metema District, northwest Ethiopia, in four randomly selected kebele administrations (thelowest level of local government). The inclusion criteria were married women aged ≥18 years residing with their husbands. Logistic regression analysis was conducted to identify factors associatedwith married women's vulnerability to HIV infection. RESULTS Participants were on average 33.70±9.50 years and nearly one-fourth (n=148, 22.5%) wereidentified as vulnerable to HIV infection (i.e., experienced sexually transmitted disease symptoms oran extramarital affair of either spouse within the past 12 months). Only 18.9% reported sexual communication with their husband. Respondents who did not discuss the risk of HIV infection withtheir husbands had fivefold odds of vulnerability (adjusted odds ratio [AOR], 5.02; 95% confidenceinterval [CI], 1.43-17.5). Those who did not have premarital sex (AOR, 0.20; 95% CI, 0.05-0.77)had no worries about HIV infection (AOR, 0.27; 95% CI, 0.08-0.94), sufficient income (AOR,0.56; 95% CI, 0.16-0.86), and less than four children (AOR, 0.69; 95% CI, 0.50-0.97) had decreased odds of being vulnerable to HIV than their counterparts. CONCLUSION Not discussing risk of HIV infection with husband was a major factor of vulnerabilityto HIV infection as was premarital sex, worry about HIV, income, and number of children. Measuresto strengthen couple's sexual communication and support economical stability is important for decreasing HIV vulnerability.
Collapse
Affiliation(s)
- Asiya Hussien
- College of Health Sciences, Ambo University, Ambo, Ethiopia
| | - Abdissa Boka
- College of Health Sciences, Addis Ababa University, Addis Ababa, Ethiopia,Corresponding author Abdissa Boka College of Health Sciences, Addis Ababa University, P.O.BOX: 4412, Addis Ababa, Ethiopia Tel: +251-912433511 E-mail:
| | - Asnake Fantu
- College of Health Sciences, Ethiopian Defense University, Bishoftu, Ethiopia
| |
Collapse
|
6
|
Community pharmacist engagement in HIV and HCV prevention: Current practices and potential for service uptake. EXPLORATORY RESEARCH IN CLINICAL AND SOCIAL PHARMACY 2021; 4:100088. [PMID: 35479840 PMCID: PMC9029914 DOI: 10.1016/j.rcsop.2021.100088] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/29/2021] [Revised: 10/10/2021] [Accepted: 10/25/2021] [Indexed: 11/20/2022] Open
Abstract
Background Objective Methods Results Conclusions Pharmacists are largely willing to help people who need HIV/HCV prevention services. Perception of HIV/HCV prevention fit with pharmacist professional identity varies. Cognitive HIV/HCV prevention services are preferred over hands-on clinical services. Pharmacists often engage in gatekeeping to limit sales of non-prescription syringes. Willingness to sell syringes potentially hinges on minimal contact with requestors.
Collapse
|
7
|
Mendicino CCP, Moodie EEM, Guimarães MDC, Pádua CAMD. Immune recovery after antiretroviral therapy initiation: a challenge for people living with HIV in Brazil. CAD SAUDE PUBLICA 2021; 37:e00143520. [PMID: 34669770 DOI: 10.1590/0102-311x00143520] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/06/2020] [Accepted: 12/17/2020] [Indexed: 11/21/2022] Open
Abstract
Immune recovery reflects health conditions. Our goal was to estimate the time it takes to achieve immune recovery and its associated factors, in people living with HIV (PLHIV), after antiretroviral therapy (ART) initiation. A historical cohort study was performed among PLHIV (> 18 years-old) in Minas Gerais State, Brazil, using data from healthcare databases. Patients initiating ART between 2009-2018, with T-CD4+ lymphocytes and viral load recorded before and after antiretroviral therapy were included. The outcome is achievement of immune recovery, defined as the first T-CD4+ > 500 cells/µL after ART initiation. Explanatory variables were age, gender, place of residence, year of ART initiation, baseline viral load and T-CD4+, viral load status, and adherence to ART at follow-up. Descriptive analysis, cumulative, and person-time incidences of immune recovery were estimated. Median-time to immune recovery was estimated using Kaplan-Meier method. Factors associated with immune recovery were assessed by Cox regression. Among 26,430 PLHIV, 8,014 (30%) were eligible. Most were male (67%), mean age 38.7 years, resided in non-central region, median-baseline T-CD4+ = 228 cells/µL (< 200 cells/µL = 43%) and viral load median-baseline = 4.7 log10 copies/mL (detectable viral load = 99%). Follow-up time = 15,872 person-years. Cumulative and incidence rate were 58% (95%CI: 57-58) (n = 4,678) and 29.47 cases/100 person-years, respectively. Median-time to immune recovery was of 22.8 months (95%CI: 21.9-24.0). Women living with HIV, younger than 38 years of age, with T-CD4+ baseline > 200 cells/µL, detectable viral load (baseline), antiretroviral therapy-adherence and undetectable viral load (follow-up) were independently associated with immune recovery. Time to immune recovery remains long and depends on early treatment and antiretroviral therapy-adherence.
Collapse
Affiliation(s)
- Cássia C P Mendicino
- Faculdade de Farmácia, Universidade Federal de Minas Gerais, Belo Horizonte, Brasil
| | | | | | | |
Collapse
|
8
|
Mitra P, Sharma P. POCT in Developing Countries. EJIFCC 2021; 32:195-199. [PMID: 34421488 PMCID: PMC8343049] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Download PDF] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
Abstract
Point of Care Technology (POCT) means acquiring clinical parameters from the place where the patient is, thus generating faster test results leading to a faster turnaround time. However, improvements in patient outcomes depend on how healthcare delivery professionals and system utilize faster turnaround times. Thus, POCT, by itself, does not lead to better clinical outcomes. Throughout the last two decades, advances in POCT have been impressive, but its impact on developing countries depends on the present healthcare infrastructure. Presently, in most developing countries, POCT is delivered in remote locations or Physicians chamber or Hospital setup of Emergency rooms, Operation Theaters, ICU. It is applied for therapeutic aid (for treatment of certain diseases like diabetes or myocardial infarction), preventive measures (for targeted screening in high-risk groups) or surveillance measures (monitoring of routine blood parameters). There are several challenges in implementing POCT like poor patient demographics, lack of workforce, training, lacking healthcare infrastructure, reluctance in physicians to accept new technology and certain technological limits. Although it may take time, solutions to these challenges will lead to a proper implementation of POCT in the developing nations. Further, integrating it with mobile phone technology will lead to higher acceptance and application. The boom of POCT will depend on the overall improvement and capacity building in the healthcare infrastructure of developing nations.
Collapse
Affiliation(s)
| | - Praveen Sharma
- Corresponding author: Prof. Praveen Sharma Department of Biochemistry All India Institute of Medical Sciences Jodhpur, 342005 India Phone: +918003996869 E-mail:
| |
Collapse
|
9
|
Undetectable viral load and HIV transmission dynamics on an individual and population level: where next in the global HIV response? Curr Opin Infect Dis 2021; 33:20-27. [PMID: 31743122 DOI: 10.1097/qco.0000000000000613] [Citation(s) in RCA: 11] [Impact Index Per Article: 3.7] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
Abstract
PURPOSE OF REVIEW To examine recent literature on the efficacy and effectiveness of HIV treatment in preventing HIV transmission through sexual exposure, at both an individual and at a population level. RECENT FINDINGS Two recent studies on the individual-level efficacy of treatment as prevention (TasP) have added to the now conclusive evidence that HIV cannot be transmitted sexually when the virus is suppressed. However, four large cluster-randomized population-level trials on universal HIV testing and treatment in Africa have not delivered the expected impact in reducing HIV incidence at a population level. Two of these trials showed no differences in HIV incidence between the intervention and control arms, one demonstrated a nonsignificant lower incidence in the intervention arm, and the fourth trial found a reduction between the communities receiving a combination prevention package and the control arm, but no difference between the immediate treatment plus the prevention package and the control arm. Factors contributing to the disconnect between individual high-level efficacy and population-level effectiveness of TasP include undiagnosed infection, delays in linkage to care, challenges in retention and adherence to antiretroviral therapy (ART), time between ART initiation and viral suppression, and stigma and discrimination. SUMMARY Suppressive ART renders people living with HIV sexually noninfectious. However, epidemic control is unlikely to be achieved by TasP alone.
Collapse
|
10
|
Nurses at the frontline of public health emergency preparedness and response: lessons learned from the HIV/AIDS pandemic and emerging infectious disease outbreaks. THE LANCET. INFECTIOUS DISEASES 2021; 21:e326-e333. [PMID: 33743850 PMCID: PMC7972309 DOI: 10.1016/s1473-3099(20)30983-x] [Citation(s) in RCA: 12] [Impact Index Per Article: 4.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 03/27/2020] [Revised: 12/03/2020] [Accepted: 12/07/2020] [Indexed: 12/20/2022]
Abstract
The years 2020–21, designated by WHO as the International Year of the Nurse and Midwife, are characterised by unprecedented global efforts to contain and mitigate the COVID-19 pandemic. Lessons learned from successful pandemic response efforts in the past and present have implications for future efforts to leverage the global health-care workforce in response to outbreaks of emerging infectious diseases such as COVID-19. Given its scale, reach, and effectiveness, the response to the HIV/AIDS pandemic provides one such valuable example, particularly with respect to the pivotal, although largely overlooked, contributions of nurses and midwives. This Personal View argues that impressive achievements in the global fight against HIV/AIDS would not have been attained without the contributions of nurses. We discuss how these contributions uniquely position nurses to improve the scale, reach, and effectiveness of response efforts to emerging infectious diseases with pandemic potential; provide examples from the responses to COVID-19, Zika virus disease, and Ebola virus disease; and discuss implications for current and future efforts to strengthen pandemic preparedness and response.
Collapse
|
11
|
Bulterys MA, Oyaro P, Brown E, Yongo N, Karauki E, Wagude J, Kingwara L, Bowen N, Njogo S, Wagner AD, Mukui I, Oluoch F, Abuogi L, Patel R, Sharma M. Costs of Point-of-Care Viral Load Testing for Adults and Children Living with HIV in Kenya. Diagnostics (Basel) 2021; 11:140. [PMID: 33477850 PMCID: PMC7832863 DOI: 10.3390/diagnostics11010140] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/16/2020] [Revised: 01/16/2021] [Accepted: 01/17/2021] [Indexed: 11/17/2022] Open
Abstract
BACKGROUND The number of people living with HIV (PLHIV) in need of treatment monitoring in low-and-middle-income countries is rapidly expanding, straining existing laboratory capacity. Point-of-care viral load (POC VL) testing can alleviate the burden on centralized laboratories and enable faster delivery of results, improving clinical outcomes. However, implementation costs are uncertain and will depend on clinic testing volume. We sought to estimate the costs of decentralized POC VL testing compared to centralized laboratory testing for adults and children receiving HIV care in Kenya. METHODS We conducted microcosting to estimate the per-patient costs of POC VL testing compared to known costs of centralized laboratory testing. We completed time-and-motion observations and stakeholder interviews to assess personnel structures, staff time, equipment costs, and laboratory processes associated with POC VL administration. Capital costs were estimated using a 5 year lifespan and a 3% annual discount rate. RESULTS We estimated that POC VL testing cost USD $24.25 per test, assuming a clinic is conducting 100 VL tests per month. Test cartridge and laboratory equipment costs accounted for most of the cost (62% and 28%, respectively). Costs varied by number of VL tests conducted at the clinic, ranging from $54.93 to $18.12 per test assuming 20 to 500 VL tests per month, respectively. A VL test processed at a centralized laboratory was estimated to cost USD $25.65. CONCLUSION POC VL testing for HIV treatment monitoring can be feasibly implemented in clinics within Kenya and costs declined with higher testing volumes. Our cost estimates are useful to policymakers in planning resource allocation and can inform cost-effectiveness analyses evaluating POC VL testing.
Collapse
Affiliation(s)
- Michelle Ann Bulterys
- Departments of Epidemiology and Global Health, University of Washington, Seattle, WA 98105, USA; (P.O.); (A.D.W.); (I.M.); (R.P.); (M.S.)
| | - Patrick Oyaro
- Departments of Epidemiology and Global Health, University of Washington, Seattle, WA 98105, USA; (P.O.); (A.D.W.); (I.M.); (R.P.); (M.S.)
- Health Innovations Kenya, Kisumu, Kenya
| | - Evelyn Brown
- Department of HIV Research, University of Washington Kenya, Nairobi, Kenya; (E.B.); (N.Y.); (E.K.)
| | - Nashon Yongo
- Department of HIV Research, University of Washington Kenya, Nairobi, Kenya; (E.B.); (N.Y.); (E.K.)
| | - Enericah Karauki
- Department of HIV Research, University of Washington Kenya, Nairobi, Kenya; (E.B.); (N.Y.); (E.K.)
| | | | - Leonard Kingwara
- National HIV Reference Laboratory, National Public Health Laboratory, Nairobi, Kenya; (L.K.); (N.B.); (F.O.)
| | - Nancy Bowen
- National HIV Reference Laboratory, National Public Health Laboratory, Nairobi, Kenya; (L.K.); (N.B.); (F.O.)
| | - Susan Njogo
- National AIDS and STI Control Programme, Ministry of Health, Nairobi 19361, Kenya;
| | - Anjuli D. Wagner
- Departments of Epidemiology and Global Health, University of Washington, Seattle, WA 98105, USA; (P.O.); (A.D.W.); (I.M.); (R.P.); (M.S.)
| | - Irene Mukui
- Departments of Epidemiology and Global Health, University of Washington, Seattle, WA 98105, USA; (P.O.); (A.D.W.); (I.M.); (R.P.); (M.S.)
| | - Frederick Oluoch
- National HIV Reference Laboratory, National Public Health Laboratory, Nairobi, Kenya; (L.K.); (N.B.); (F.O.)
| | - Lisa Abuogi
- Department of Pediatrics, University of Colorado, Denver, CO 80045, USA;
| | - Rena Patel
- Departments of Epidemiology and Global Health, University of Washington, Seattle, WA 98105, USA; (P.O.); (A.D.W.); (I.M.); (R.P.); (M.S.)
- Department of Medicine, Division of Allergy and Infectious Diseases, University of Washington, Seattle, WA 98105, USA
| | - Monisha Sharma
- Departments of Epidemiology and Global Health, University of Washington, Seattle, WA 98105, USA; (P.O.); (A.D.W.); (I.M.); (R.P.); (M.S.)
| |
Collapse
|
12
|
Kurniasari MD, Huruta AD, Tsai HT, Lee CW. Forecasting future HIV infection cases: evidence from Indonesia. SOCIAL WORK IN PUBLIC HEALTH 2021; 36:12-25. [PMID: 33272146 DOI: 10.1080/19371918.2020.1851332] [Citation(s) in RCA: 3] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 06/12/2023]
Abstract
Countries throughout the world, including Indonesia, are facing a complex problem with regards to HIV infection incidences and its prevalence. This is despite some local governments in some provinces of Indonesia working together with the Social Ministry of Indonesia to eradicate prostitution. There are high numbers of HIV sub-types in Indonesia such as HIV-1 (CRF01_AE and B). The forecast was conducted with the Autoregressive Integrated Moving Average model. The ARMA (1,1) was observed to be the best model for forecasting the number of HIV patients in Indonesia. This forecasting has been done since March 2019. Based on its dynamic forecasting with ARMA (1,1), this study proved the number of HIV-positive patients, from 2019 to 2030, had increased from 22,679 to 36,255, by almost 37% within 12 years. Indonesia is facing a growing trend in the number of new HIV cases, until 2030 which caused by stopped their follow-up treatments or they have ceased in consuming the Antiretroviral drugs even though the Indonesian government was provided national health insurance which covers the Antiretroviral drug and a limited number of health-care services providing the Antiretroviral therapy. Therefore, investigations focusing on estimate the number of HIV patients in Indonesia is an important finding. The information can be used as a resource for policy and decision making for plans and programs.
Collapse
Affiliation(s)
- Maria Dyah Kurniasari
- School of Nursing, College of Nursing, Taipei Medical University, Taipei City, Republic of Tiongkok
- Department of Nursing, Faculty of Medicine and Health Science, Universitas Kristen Satya Wacana, Salatiga City, Indonesia
| | - Andrian Dolfriandra Huruta
- Program in Business, College of Business, Chung Yuan Christian University, Taoyuan City, Taiwan, ROC
- Department of Economics, Faculty of Economic and Business, Universitas Kristen Satya Wacana, Salatiga City, Indonesia
| | - Hsiu Ting Tsai
- School of Nursing, College of Nursing, Taipei Medical University, Taipei City, Republic of Tiongkok
- School of Nursing, Post-Baccalaureate Program in Nursing, Taipei Medical University, Taipei City, Republic of China
| | - Cheng-Wen Lee
- Department of International Business, College of Business, Chung Yuan Christian University, Taoyuan City, Taiwan, ROC
| |
Collapse
|
13
|
Preiser W, van Zyl GU. Pooled testing: A tool to increase efficiency of infant HIV diagnosis and virological monitoring. Afr J Lab Med 2020; 9:1035. [PMID: 32934914 PMCID: PMC7479369 DOI: 10.4102/ajlm.v9i2.1035] [Citation(s) in RCA: 4] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/24/2019] [Accepted: 04/15/2020] [Indexed: 01/04/2023] Open
Abstract
Background Pooled testing, or pooling, has been used for decades to efficiently diagnose relatively rare conditions, such as infection in blood donors. Programmes for the prevention of mother-to-child transmission of HIV and for antiretroviral therapy (ART) are being rolled out in much of Africa and are largely successful. This increases the need for early infant diagnosis (EID) of HIV using qualitative nucleic acid testing and for virological monitoring of patients on ART using viral load testing. While numbers of patients needing testing are increasing, infant HIV infections and ART failures are becoming rarer, opening an opportunity for pooled testing approaches. Aim This review highlights the need for universal EID and viral load coverage as well as the challenges faced. We introduce the concept of pooled testing and highlight some important considerations before giving an overview of studies exploring pooled testing for EID and virological monitoring. Results For ART monitoring, pooling has been shown to be accurate and efficient; for EID it has not been tried although modelling shows it to be promising. The final part attempts to place pooling into the context of current mother-to-child transmission of HIV and ART programmes and their expected trajectories over the next years. Conclusion Several points warrant consideration: pre-selection to exclude samples with an elevated pre-test probability of positivity from pooled testing, the use of dried blood or plasma spots, and choosing a pooling strategy that is both practically feasible and economical. Finally, novel ideas are suggested to make pooling even more attractive.
Collapse
Affiliation(s)
- Wolfgang Preiser
- Division of Medical Virology, Department of Pathology, Faculty of Medicine and Health Sciences, Stellenbosch University, Cape Town, South Africa.,National Health Laboratory Service (NHLS) Tygerberg, Cape Town, South Africa
| | - Gert U van Zyl
- Division of Medical Virology, Department of Pathology, Faculty of Medicine and Health Sciences, Stellenbosch University, Cape Town, South Africa.,National Health Laboratory Service (NHLS) Tygerberg, Cape Town, South Africa
| |
Collapse
|
14
|
Field Suitability and Diagnostic Accuracy of the Biocentric Open Real-Time PCR Platform for Dried Blood Spot-Based HIV Viral Load Quantification in Eswatini. J Acquir Immune Defic Syndr 2020; 82:96-104. [PMID: 31408452 PMCID: PMC6727953 DOI: 10.1097/qai.0000000000002101] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/10/2023]
Abstract
Supplemental Digital Content is Available in the Text. Background: To assess the performance and suitability of dried blood spot (DBS) sampling using filter paper to collect blood for viral load (VL) quantification under routine conditions. Methods: We compared performance of DBS VL quantification using the Biocentric method with plasma VL quantification using Roche and Biocentric as reference methods. Adults (≥18 years) were enrolled at 2 health facilities in Eswatini from October 12, 2016 to March 1, 2017. DBS samples were prepared through finger-prick by a phlebotomist (DBS-1), and through the pipetting of whole venous blood by a phlebotomist (DBS-2) and by a laboratory technologist (DBS-3). We calculated the VL-testing completion rate, correlation, and agreement, as well as diagnostic accuracy estimates at the clinical threshold of 1000 copies/mL. Results: Of 362 patients enrolled, 1066 DBS cards (DBS-1: 347; DBS-2: 359; DBS-3: 360) were tested. Overall, test characteristics were comparable between DBS-sampling methods, irrespective of the reference method. The Pearson correlation coefficients ranged from 0.67 to 0.82 (P < 0.001) for different types of DBS sampling using both reference methods, and the Bland–Altman difference ranged from 0.15 to 0.30 log10 copies/mL. Sensitivity estimates were from 85.3% to 89.2% and specificity estimates were from 94.5% to 98.6%. The positive predictive values were between 87.0% and 96.5% at a prevalence of 30% VL elevations, and negative predictive values were between 93.7% and 95.4%. Conclusions: DBS VL quantification using the newly configured Biocentric method can be part of contextualized VL-testing strategies, particularly for remote settings and populations with higher viral failure rates.
Collapse
|
15
|
Drain PK, Dorward J, Violette LR, Quame-Amaglo J, Thomas KK, Samsunder N, Ngobese H, Mlisana K, Moodley P, Donnell D, Barnabas RV, Naidoo K, Abdool Karim SS, Celum C, Garrett N. Point-of-care HIV viral load testing combined with task shifting to improve treatment outcomes (STREAM): findings from an open-label, non-inferiority, randomised controlled trial. Lancet HIV 2020; 7:e229-e237. [PMID: 32105625 DOI: 10.1016/s2352-3018(19)30402-3] [Citation(s) in RCA: 60] [Impact Index Per Article: 15.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/17/2019] [Revised: 10/27/2019] [Accepted: 11/15/2019] [Indexed: 11/16/2022]
Abstract
BACKGROUND Monitoring HIV treatment with laboratory testing introduces delays for providing appropriate care in resource-limited settings. The aim of our study was to determine whether point-of-care HIV viral load testing with task shifting changed treatment and care outcomes for adults on antiretroviral therapy (ART) when compared with standard laboratory viral load testing. METHODS We did an open-label, non-inferiority, randomised controlled trial in a public clinic in Durban, South Africa. We enrolled HIV-positive adults (aged ≥18 years) who presented for their first routine HIV viral load test 6 months after ART initiation. Individuals were randomly assigned by a random number allocation sequence to receive either point-of-care viral load testing at enrolment and after 6 months with task shifting to enrolled nurses (intervention group), or laboratory viral load testing (standard-of-care group). The primary outcome was combined viral suppression (<200 copies per mL) and retention at 12 months after enrolment. A non-inferiority margin of 10% was used. Analysis was done by intention to treat. This study was registered with ClinicalTrials.gov, NCT03066128. FINDINGS Between Feb 24, 2017, and Aug 23, 2017, we screened 657 participants, and 390 were enrolled and randomly assigned to either the intervention group (n=195) or standard-of-care group (n=195). 175 (90%) individuals in the intervention group and 148 (76%) individuals in the standard-of-care group had the primary outcome of retention with viral suppression, a difference of 13·9% (95% CI 6·4-21·2; p<0·00040). 182 participants (93%) in the intervention group had viral suppression compared with 162 (83%) in the standard-of-care group (difference 10·3%, 3·9-16·8; p=0·0025); 180 (92%) and 162 (85%) were retained in care (7·7%, 1·3-14·2; p=0·026). There were no adverse events related to point-of-care HIV viral load testing or task shifting. INTERPRETATION Point-of-care viral load testing combined with task shifting significantly improved viral suppression and retention in HIV care. Point-of-care testing can simplify treatment and improve outcomes for HIV-positive adults receiving ART in resource-limited settings. FUNDING National Institute of Allergy and Infectious Diseases.
Collapse
Affiliation(s)
- Paul K Drain
- Department of Global Health, School of Public Health and School of Medicine, University of Washington, Seattle, WA, USA; Department of Medicine, School of Medicine, University of Washington, Seattle, WA, USA; Department of Epidemiology, School of Public Health, University of Washington, Seattle, WA, USA.
| | - Jienchi Dorward
- Nuffield Department of Primary Care Health Sciences, University of Oxford, Oxford, UK; Centre for the AIDS Programme of Research in South Africa, University of KwaZulu-Natal, Durban, South Africa
| | - Lauren R Violette
- Department of Medicine, School of Medicine, University of Washington, Seattle, WA, USA
| | - Justice Quame-Amaglo
- Department of Global Health, School of Public Health and School of Medicine, University of Washington, Seattle, WA, USA
| | - Katherine K Thomas
- Department of Global Health, School of Public Health and School of Medicine, University of Washington, Seattle, WA, USA
| | - Natasha Samsunder
- Centre for the AIDS Programme of Research in South Africa, University of KwaZulu-Natal, Durban, South Africa
| | - Hope Ngobese
- Prince Cyril Zulu Communicable Disease Clinic, Durban Municipality, Durban, South Africa
| | - Koleka Mlisana
- School of Laboratory Medicine and Medical Sciences, University of KwaZulu-Natal, Durban, South Africa; National Health Laboratory Service, Durban, South Africa
| | - Pravikrishnen Moodley
- School of Laboratory Medicine and Medical Sciences, University of KwaZulu-Natal, Durban, South Africa; National Health Laboratory Service, Durban, South Africa; Department of Virology, Inkosi Albert Luthuli Central Hospital, Cato Manor, South Africa
| | - Deborah Donnell
- Department of Global Health, School of Public Health and School of Medicine, University of Washington, Seattle, WA, USA
| | - Ruanne V Barnabas
- Department of Global Health, School of Public Health and School of Medicine, University of Washington, Seattle, WA, USA; Department of Medicine, School of Medicine, University of Washington, Seattle, WA, USA
| | - Kogieleum Naidoo
- Centre for the AIDS Programme of Research in South Africa, University of KwaZulu-Natal, Durban, South Africa; School of Nursing and Public Health, University of KwaZulu-Natal, Durban, South Africa; CAPRISA-MRC HIV-TB Pathogenesis and Treatment Research Unit, and Doris Duke Medical Research Institute, University of KwaZulu-Natal, Durban, South Africa
| | - Salim S Abdool Karim
- Centre for the AIDS Programme of Research in South Africa, University of KwaZulu-Natal, Durban, South Africa; School of Nursing and Public Health, University of KwaZulu-Natal, Durban, South Africa; Department of Epidemiology, Columbia University, New York, NY, USA
| | - Connie Celum
- Department of Global Health, School of Public Health and School of Medicine, University of Washington, Seattle, WA, USA; Department of Medicine, School of Medicine, University of Washington, Seattle, WA, USA
| | - Nigel Garrett
- Centre for the AIDS Programme of Research in South Africa, University of KwaZulu-Natal, Durban, South Africa; School of Nursing and Public Health, University of KwaZulu-Natal, Durban, South Africa
| |
Collapse
|
16
|
Abstract
PURPOSE OF REVIEW This article aims at examining the key recent advances in the field of EID, as well as at discussing approaches for resolving the major bottlenecks faced by health systems in the identification and linkage to care of HIV-infected infants. RECENT FINDINGS Programmatic experience in South Africa and research in other high-burden countries showed that birth HIV testing is accurate, feasible and has the potential to decrease infant mortality. Substantial evidence has mounted on the accuracy of point-of-care testing for EID, including for birth testing. Importantly, it has now been demonstrated that point-of-care EID improves the rate of results return to patients and has significant positive effect on ART initiation rates. Finally, there are good examples of how EID fits into more comprehensive and integrated packages of services covering the antenatal, birth and postpartum periods. SUMMARY Point-of-care testing for EID, including for birth testing, should be widely implemented to complement laboratory-based testing in high-burden countries. Most of the current barriers for timely EID testing and ART initiation in infants are related to weaknesses in the health system, and will require the implementation of comprehensive approaches aiming at scaling-up these interventions within strengthened primary healthcare services.
Collapse
|
17
|
Luo R, Markby J, Sacks J, Vojnov L. Systematic review of the accuracy of plasma preparation tubes for HIV viral load testing. PLoS One 2019; 14:e0225393. [PMID: 31751392 PMCID: PMC6874077 DOI: 10.1371/journal.pone.0225393] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/22/2019] [Accepted: 11/03/2019] [Indexed: 01/28/2023] Open
Abstract
Expanding access to HIV viral load testing is essential to improving the care and treatment of people living with HIV/AIDS and ending the AIDS epidemic. Though significant investments have been made in the past five years, many high burden, low resource countries continue to have viral load access rates below 50%. Plasma preparation tubes (PPTs) can simplify storage, transport, and preparation of plasma used for viral load testing. A systematic review was conducted to evaluate the accuracy of plasma preparation tubes for HIV viral load testing. Study results regarding the accuracy of PPT viral load measurements across various storage and transportation conditions were examined. The quality of evidence was evaluated using GRADE and QUADAS-2 criteria. The review identified 16 studies using PPTs with data from 6,141 individuals from 1995 to 2014. Overall the quality of evidence was rated as moderate, with unclear applicability for studies evaluating viral load assays that are no longer commercially available. Significantly elevated viral load results (>0.3 log copies/ml difference) have been observed with PPTs; however, when manufacturer handling instructions are followed, when plasma is aliquoted into a secondary tube, or when PPTs are centrifuged prior to testing, PPT results only differed from standard EDTA plasma testing using commercially available viral load assays by a range on average of -0.03 to +0.08 log copies/ml across studies. Although spuriously elevated viral load results have been observed with PPTs, following proper sample handing techniques have been shown to provide accurate results. PPTs, therefore, provide a high quality alternative specimen type for countries seeking solutions to infrastructure and specimen transportation challenges in an effort to scale-up viral load testing and achieve 90-90-90 targets.
Collapse
Affiliation(s)
- Robert Luo
- World Health Organization, Geneva, Switzerland
- * E-mail:
| | - Jessica Markby
- Clinton Health Access Initiative, Boston, Massachusetts, United States of America
| | - Jilian Sacks
- Clinton Health Access Initiative, Boston, Massachusetts, United States of America
| | - Lara Vojnov
- World Health Organization, Geneva, Switzerland
| |
Collapse
|
18
|
Beck EJ, Mandalia S, DongmoNguimfack B, Pinheiro E, 't Hoen E, Boulet P, Stover J, Gupta A, Juneja S, Habiyambere V, Ghys P, Nunez C. Does the political will exist to bring quality-assured and affordable drugs to low- and middle-income countries? Glob Health Action 2019; 12:1586317. [PMID: 30983547 PMCID: PMC6484498 DOI: 10.1080/16549716.2019.1586317] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/21/2023] Open
Abstract
Background: Increased coverage with antiretroviral therapy for people living with HIV in low- and middle-income countries has increased their life expectancy associated with non-HIV comorbidities and the need for quality-assured and affordable non-communicable diseases drugs . Funders are leaving many middle-income countries that will have to pay and provide quality-assured and affordable HIV and non-HIV drugs, including for non-communicable diseases. Objective: To estimate costs for originator and generic antiretroviral therapy as the number of people living with HIV are projected to increase between 2016 and 2026, and discuss country, regional and global factors associated with increased access to generic drugs. Methods: Based on estimates of annual demand and prices, annual cost estimates were produced for generic and originator antiretroviral drug prices in low- and middle-income countries and projected for 2016–2026. Results: Drug costs varied between US$1.5 billion and US$4.8 billion for generic drugs and US$ 8.2 billion and US$16.5 billion for originator drugs between 2016 and 2026. Discussion: The global HIV response increased access to affordable generic drugs in low- and middle-income countries. Cheaper active pharmaceutical ingredients and market competition were responsible for reduced drug costs. The development and implementation of regulatory changes at country, regional and global levels, covering intellectual property rights and public health, and flexibilities in patent laws enabled prices to be reduced. These changes have not yet been applied in many low- and middle-income countries for HIV, nor for other infectious and non-communicable diseases, that lack the profile and political attention of HIV. Licensing backed up with Trade-Related Aspects of Intellectual Property Rights safeguards should become the norm to provide quality-assured and affordable drugs within competitive generic markets. Conclusion: Does the political will exist among policymakers and other stakeholders to develop and implement these country, regional and global frameworks for non-HIV drugs as they did for antiretroviral drugs?
Collapse
Affiliation(s)
| | | | | | | | | | | | | | | | | | | | - Peter Ghys
- a Programme Branch , UNAIDS , Geneva , Switzerland
| | - Cesar Nunez
- a Programme Branch , UNAIDS , Geneva , Switzerland
| |
Collapse
|
19
|
Girdwood SJ, Nichols BE, Moyo C, Crompton T, Chimhamhiwa D, Rosen S. Optimizing viral load testing access for the last mile: Geospatial cost model for point of care instrument placement. PLoS One 2019; 14:e0221586. [PMID: 31449559 PMCID: PMC6709899 DOI: 10.1371/journal.pone.0221586] [Citation(s) in RCA: 22] [Impact Index Per Article: 4.4] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/01/2019] [Accepted: 08/10/2019] [Indexed: 11/19/2022] Open
Abstract
INTRODUCTION Viral load (VL) monitoring programs have been scaled up rapidly, but are now facing the challenge of providing access to the most remote facilities (the "last mile"). For the hardest-to-reach facilities in Zambia, we compared the cost of placing point of care (POC) viral load instruments at or near facilities to the cost of an expanded sample transportation network (STN) to deliver samples to centralized laboratories. METHODS We extended a previously described geospatial model for Zambia that first optimized a STN for centralized laboratories for 90% of estimated viral load volumes. Amongst the remaining 10% of volumes, facilities were identified as candidates for POC placement, and then instrument placement was optimized such that access and instrument utilization is maximized. We evaluated the full cost per test under three scenarios: 1) POC placement at all facilities identified for POC; 2)an optimized combination of both on-site POC placement and placement at facilities acting as POC hubs; and 3) integration into the centralized STN to allow use of centralized laboratories. RESULTS For the hardest-to-reach facilities, optimal POC placement covered a quarter of HIV-treating facilities. Scenario 2 resulted in a cost per test of $39.58, 6% less than the cost per test of scenario 1, $41.81. This is due to increased POC instrument utilization in scenario 2 where facilities can act as POC hubs. Scenario 3 was the most costly at $53.40 per test, due to high transport costs under the centralized model ($36 per test compared to $12 per test in scenario 2). CONCLUSIONS POC VL testing may reduce the costs of expanding access to the hardest-to-reach populations, despite the cost of equipment and low patient volumes. An optimal combination of both on-site placement and the use of POC hubs can reduce the cost per test by 6-35% by reducing transport costs and increasing instrument utilization.
Collapse
Affiliation(s)
- Sarah J. Girdwood
- Health Economics and Epidemiology Research Office, Department of Internal Medicine, School of Clinical Medicine, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa
| | - Brooke E. Nichols
- Health Economics and Epidemiology Research Office, Department of Internal Medicine, School of Clinical Medicine, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa
- Department of Global Health, School of Public Health, Boston University, Boston, MA, United States of America
| | | | - Thomas Crompton
- Right to Care, GIS Mapping Department, Johannesburg, South Africa
| | | | - Sydney Rosen
- Health Economics and Epidemiology Research Office, Department of Internal Medicine, School of Clinical Medicine, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa
- Department of Global Health, School of Public Health, Boston University, Boston, MA, United States of America
| |
Collapse
|
20
|
The missed potential of CD4 and viral load testing to improve clinical outcomes for people living with HIV in lower-resource settings. PLoS Med 2019; 16:e1002820. [PMID: 31141516 PMCID: PMC6541248 DOI: 10.1371/journal.pmed.1002820] [Citation(s) in RCA: 23] [Impact Index Per Article: 4.6] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 12/28/2022] Open
Abstract
In a Policy Forum, Peter Ehrenkranz and colleagues discuss the contribution of CD4 and viral load testing to outcomes for people with HIV in low- and middle-income countries.
Collapse
|
21
|
Wexler C, Kamau Y, Halder R, Brown M, Maloba M, Mabachi N, Sandbulte M, Gautney B, Goggin K, Odeny T, Finocchario-Kessler S. "Closing the Gap": Provider Recommendations for Implementing Birth Point of Care HIV Testing. AIDS Behav 2019; 23:1073-1083. [PMID: 30542834 DOI: 10.1007/s10461-018-2363-3] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/11/2023]
Abstract
Delays in traditional HIV DNA PCR testing for early infant diagnosis (EID) at 6 weeks of age result in late antiretroviral treatment (ART). Birth point of care (POC) testing is an emerging strategy with the potential to streamline EID services. We elicited providers' recommendations for introducing birth POC testing to guide strategies in Kenya and similar settings. We conducted formative interviews with 26 EID providers from four Kenyan hospitals prior to POC implementation. Providers discussed the need for comprehensive training, covering both EID and POC-specific topics for all key personnel. Providers highlighted equipment considerations, such as protocols for maintenance and safe storage. Providers emphasized the need for maternal counseling to ensure patient acceptance and most agreed that specimen collection for birth POC testing should occur in the maternity department and supported a multidisciplinary approach. Though most providers supported ART initiation based on a positive birth POC result, a few expressed concerns with result validity. To maximize implementation success, provider training, equipment security, maternal counseling, and logistics of testing must be planned and communicated to providers.
Collapse
|
22
|
Toward Improving Accessibility of Point-of-Care Diagnostic Services for Maternal and Child Health in Low- and Middle-Income Countries. POINT OF CARE 2019; 18:17-25. [PMID: 30886544 PMCID: PMC6407818 DOI: 10.1097/poc.0000000000000180] [Citation(s) in RCA: 21] [Impact Index Per Article: 4.2] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/25/2023]
Abstract
Point-of-care (POC) testing can improve health care provision in settings with limited access to health care services. Access to POC diagnostic services has shown potential to alleviate some diagnostic challenges and delays associated with laboratory-based methods in low- and middle-income countries. Improving accessibility to POC testing (POCT) services during antenatal and perinatal care is among the global health priorities to improve maternal and child health. This review provides insights on the availability of POC testing designed for diagnosing HIV, syphilis, and malaria in pregnancy to improve maternal and child health. In addition, factors such as accessibility of POC testing, training of health work force, and the efficiency of POC testing services delivery in low- and middle-income countries are discussed. A framework to help increase access to POC diagnostic services and improve maternal and child health outcomes in low- and middle-income countries is proposed.
Collapse
|